Drs. Bridgewater and Meric-Bernstram to Chair
The 8th Annual Cholangiocarcinoma Foundation Conference will be held virtually March 31st- April 2nd, 2021. John Bridgewater, MD, PhD of the UCL Cancer Institute, London and Funda Meric- Bernstram, MD of MD Anderson Cancer Center will Co-Chair the event.
Dr. Bridgewater specializes in gastrointestinal oncology, with a particular interest in biliary tract cancers and carcinomas of unknown primary origin. He leads the National Cancer Research Institute subgroup in biliary tract malignancy and is actively involved in the research portfolio.
Dr. Meric-Bernstam is the Chair of the Department of Investigational Cancer Therapeutics -- the Phase I Program as well as the Medical Director of the Institute for Personalized Cancer Therapy (IPCT) at MD Anderson Cancer Center. Her clinical research is focused on Phase I /II trials with a focus on novel mechanisms of action, novel combination therapies, and biomarkers to predict and monitor drug response.
The Cholangiocarcinoma Foundation (CCF) is the leading global resource for cholangiocarcinoma, a rare cancer of the bile duct. The Annual Conference continues to be the premier source for the presentation of cutting-edge research, innovative therapies, and patient education in the field of cholangiocarcinoma and is always a highlight for all that attend. More than 700 Patients & Caregivers, 300 Clinicians and Researchers, and 400 Industry representatives and sponsors hailing from 49 states and 42 countries participated in the 2020 Annual Conference.
"Stacie Lindsey, President, and Founder said “This one-of-a-kind annual gathering convenes the leading medical and scientific experts in cholangiocarcinoma. Together with industry partners, regulatory representatives, patients and caregivers, it brings together all the needed elements to drive critical change and work toward innovative solutions for patients."
Event Co-Chairs, John Bridgewater, MD, PhD of the UCL Cancer Institute, London and Funda Meric-Bernstram, MD of MD Anderson Cancer Center said, “We are honored to have been chosen to co-chair the 2021 Cholangiocarcinoma Foundation Annual Conference. What makes this meeting stand out from others is the close involvement and participation of the cholangiocarcinoma community that brings a vitality and a sharpened sense of purpose to these very special few days. We look forward to sharing the latest developments and innovations in science, research and treatments for cholangiocarcinoma.”